On the public citation graph
Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants
0 signed · 72 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archinte.165.12.1363openalex-snapshot
Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002
inferredcites →https://doi.org/10.1001/archinte.167.16.1752openalex-snapshot
Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005
inferredcites →https://doi.org/10.1001/archinternmed.2011.89openalex-snapshot
The FDA Drug Safety Surveillance Program: Adverse Event Reporting Trends
inferredcites →https://doi.org/10.1002/pdsopenalex-snapshot
Factors Predisposing an Abstract To Be Accepted for Oral Presentation
inferredcites →https://doi.org/10.1002/pds.1323openalex-snapshot
Data mining for signals in spontaneous reporting databases: proceed with caution
inferredcites →https://doi.org/10.1002/pds.3561openalex-snapshot
AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System
inferredcites →https://doi.org/10.1002/pds.3626openalex-snapshot
Acute kidney injury during concomitant use of valacyclovir and loxoprofen: detecting drug-drug interactions in a spontaneous reporting system
inferredcites →https://doi.org/10.1002/phar.1519openalex-snapshot
How Safe Are Recently FDA ‐Approved Antimicrobials? A Review of the FDA Adverse Event Reporting System Database
inferredcites →https://doi.org/10.1007/s11096-010-9372-2openalex-snapshot
Detection of adverse drug reactions through the minimum basic data set
inferredcites →https://doi.org/10.1007/s40264-013-0124-9openalex-snapshot
Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia
inferredcites →https://doi.org/10.1016/j.jsps.2014.04.005openalex-snapshot
Use of an entacapone-containing drug combination and risk of death: Analysis of the FDA AERS (FAERS) database
inferredcites →https://doi.org/10.1016/j.jval.2015.03.502openalex-snapshot
Serious adverse Drug events reported to the Food and Drug Administration (FDA): analysis of the FDA adverse event reporting system (FAERS) 2006-2011 database
inferredcites →https://doi.org/10.1016/s1574-1400(08)00012-1openalex-snapshot
PubChem: Integrated Platform of Small Molecules and Biological Activities
inferredcites →https://doi.org/10.1046/j.0306-5251.2001.01501.xopenalex-snapshot
Determinants of signal selection in a spontaneous reporting system for adverse drug reactions
inferredcites →https://doi.org/10.1093/nar/gkq1126openalex-snapshot
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
inferredcites →https://doi.org/10.1177/0333102413499649openalex-snapshot
Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database
inferredcites →https://doi.org/10.1186/1471-2105-15-17openalex-snapshot
Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection
inferredcites →https://doi.org/10.1186/1743-8462-6-18openalex-snapshot
Medication safety in acute care in Australia: where are we now? Part 1: a review of the extent and causes of medication problems 2002–2008
inferredcites →https://doi.org/10.2165/00002018-200730060-00009openalex-snapshot
???Extreme Duplication??? in the US FDA Adverse Events Reporting System Database
inferredcites →https://doi.org/10.4081/dts.2013.e4openalex-snapshot
Development of a drug safety ePlatform for physicians, pharmacists, and consumers based on post-marketing adverse events
inferredcites →https://doi.org/10.5772/50095openalex-snapshot
Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS)
inferredcites →https://doi.org/10.7150/ijms.6048openalex-snapshot
Data Mining of the Public Version of the FDA Adverse Event Reporting System
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4788499openalex-extracted
Integrated Analysis of VEGF and VEGFR Inhibitor-Induced Hypertension: Insights from Pharmacovigilance, Clinical Data, and Animal Models
inferred← citeshttps://doi.org/10.2139/ssrn.4804332openalex-extracted
Integrated Analysis of VEGF and VEGFR Inhibitor-Induced Hypertension: Insights from Pharmacovigilance, Clinical Data, and Animal Models
inferred← citeshttps://doi.org/10.1002/imo2.70014openalex-snapshot
Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy
inferred← citeshttps://doi.org/10.1002/pds.5743openalex-snapshot
Descriptive analysis on disproportionate medication errors and associated patient characteristics in the Food and Drug Administration's Adverse Event Reporting System
inferred← citeshttps://doi.org/10.1002/pds.70043openalex-snapshot
Investigating the Safety Profile of Fast‐Track COVID ‐19 Drugs Using the FDA Adverse Event Reporting System Database: A Comparative Observational Study
inferred← citeshttps://doi.org/10.1002/prp2.1236openalex-snapshot
Clinical drug interactions between linezolid and other antibiotics: For adverse drug event monitoring
inferred← citeshttps://doi.org/10.1007/978-1-4939-7312-5_2openalex-snapshot
Uncovering Innovation Features and Emerging Technologies in Molecular Biology through Patent Analysis
inferred← citeshttps://doi.org/10.1007/978-3-031-87647-9_12openalex-snapshot
Evaluating Llama-3.1 for Adverse Drug Event Entity and Relationship Extraction Across Prompting Techniques
inferred← citeshttps://doi.org/10.1007/s00210-026-05254-4openalex-snapshot
Tofacitinib safety in inflammatory bowel disease: a disproportionality analysis of the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1007/s11096-025-01925-zopenalex-snapshot
Peripheral neuropathy associated with immunomodulatory drugs: a pharmacovigilance analysis based on the FDA adverse event reporting system database
inferred← citeshttps://doi.org/10.1007/s40259-018-0285-2openalex-snapshot
Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)
inferred← citeshttps://doi.org/10.1007/s40264-023-01391-4openalex-snapshot
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
inferred← citeshttps://doi.org/10.1016/j.clinthera.2025.04.017openalex-snapshot
Comparative Analysis of Adverse Events Linked to PEG-rhG-CSF and rhG-CSF in Real-World Settings: Disproportionate Examination of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
inferred← citeshttps://doi.org/10.1016/j.numecd.2018.02.014openalex-snapshot
Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems
inferred← citeshttps://doi.org/10.1016/j.renene.2018.02.101openalex-snapshot
Wind energy research in Mexico
inferred← citeshttps://doi.org/10.1021/acs.chemrestox.0c00294openalex-snapshot
Systematic Analysis of Protein Targets Associated with Adverse Events of Drugs from Clinical Trials and Postmarketing Reports
inferred← citeshttps://doi.org/10.1021/acs.chemrestox.8b00159openalex-snapshot
Information-Derived Mechanistic Hypotheses for Structural Cardiotoxicity
inferred← citeshttps://doi.org/10.1038/s41598-020-80569-7openalex-snapshot
Adverse outcomes associated with the treatment of Toxoplasma infections
inferred← citeshttps://doi.org/10.1080/14740338.2024.2368817openalex-snapshot
The evolving role of disproportionality analysis in pharmacovigilance
inferred← citeshttps://doi.org/10.1080/14740338.2024.2443781openalex-snapshot
Hematopoietic adverse events associated with PARP inhibitors: A FAERS database study
inferred← citeshttps://doi.org/10.1080/14740338.2025.2496434openalex-snapshot
Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS database
inferred← citeshttps://doi.org/10.1093/bib/bbaa363openalex-snapshot
Automation in signal management in pharmacovigilance—an insight
inferred← citeshttps://doi.org/10.1093/database/baab068openalex-snapshot
Mining drug–target and drug–adverse drug reaction databases to identify target–adverse drug reaction relationships
inferred← citeshttps://doi.org/10.1097/md.0000000000041721openalex-snapshot
Comprehensive evaluation of flumazenil adverse reactions: Insights from FAERS data and signal detection algorithms
inferred← citeshttps://doi.org/10.1101/2020.06.12.135939openalex-snapshot
Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and post-marketing reports
inferred← citeshttps://doi.org/10.1136/bmjopen-2023-081990openalex-snapshot
Navigating duplication in pharmacovigilance databases: a scoping review
inferred← citeshttps://doi.org/10.1139/cjpp-2024-0078openalex-snapshot
Analysis of literature-derived duplicate records in the FDA Adverse Event Reporting System (FAERS) database
inferred← citeshttps://doi.org/10.11588/ip.2015.2.23784openalex-snapshot
Erstellung wiederverwendbarer RDF-Geodaten mit Google Refine
inferred← citeshttps://doi.org/10.11606/d.96.2017.tde-08082017-170651openalex-snapshot
Redes de cooperação para desenvolvimento tecnológico dos biocombustíveis: mapeamento a partir de cotitularidade em patentes
inferred← citeshttps://doi.org/10.11606/d.96.2019.tde-03092019-091438openalex-snapshot
Análise da colaboração entre empresas do setor de cosméticos: um estudo a partir de patentes
inferred← citeshttps://doi.org/10.1186/s10194-025-02091-3openalex-snapshot
Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.1186/s12885-025-14743-3openalex-snapshot
Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2340823/v1openalex-snapshot
Determining Mortality Likelihood of Opioid Drug Combinations using Decision Tree Analysis
inferred← citeshttps://doi.org/10.2139/ssrn.5390672openalex-snapshot
Enhancing Safety Signaling: Integrating Clinical Trials and Post-Marketing Adverse Event Reports
inferred← citeshttps://doi.org/10.2196/21811openalex-snapshot
Developing a Standardized and Reusable Method to Link Distributed Health Plan Databases to the National Death Index: Methods Development Study Protocol
inferred← citeshttps://doi.org/10.3389/fbinf.2022.906644openalex-snapshot
Prediction of Adverse Drug Reaction Linked to Protein Targets Using Network-Based Information and Machine Learning
inferred← citeshttps://doi.org/10.3389/fddsv.2021.768792openalex-snapshot
Deep Learning Prediction of Adverse Drug Reactions in Drug Discovery Using Open TG–GATEs and FAERS Databases
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1488853openalex-snapshot
Comprehensive analysis of VEGF/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1902939openalex-snapshot
Immune checkpoint inhibitor-related thyroid dysfunction during treatment of lung cancer: a disproportionality analysis based on the FDA adverse event reporting system
inferred← citeshttps://doi.org/10.3389/fmed.2021.644871openalex-snapshot
Associations Between Stevens–Johnson Syndrome and Infection: Overview of Pharmacoepidemiological Studies
inferred← citeshttps://doi.org/10.3389/fmed.2026.1736592openalex-snapshot
Adverse events related to drug–drug interactions in tocilizumab combination therapy: a retrospective analysis and clinical implications
inferred← citeshttps://doi.org/10.3389/fmed.2026.1766601openalex-snapshot
Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database
inferred← citeshttps://doi.org/10.3389/fphar.2024.1292163openalex-snapshot
Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events
inferred← citeshttps://doi.org/10.3389/fphar.2026.1731545openalex-snapshot
Real-world landscape of drug-related ocular injuries: a retrospective pharmacovigilance study
inferred← citeshttps://doi.org/10.4236/ojd.2020.92002openalex-snapshot
Detection and Evaluation of Adverse Drug Reaction Signals of Antidepressants Based on FDA Adverse Event Reporting System Database
inferred← citeshttps://doi.org/10.48550/arxiv.2010.05411openalex-snapshot
Deep Learning Prediction of Adverse Drug Reactions Using Open TG-GATEs and FAERS Databases
inferred← citeshttps://doi.org/10.5585/geas.v8i3.15777openalex-snapshot
METHODOLOGICAL PROPOSAL FOR THE USE OF PATENTS IN RESEARCH OF INTERORGANIZATIONAL COLLABORATION NETWORKS FOR INNOVATION
inferred← citeshttps://doi.org/10.5664/jcsm.6452openalex-snapshot
Spontaneous Adverse Event Reports Associated with Zolpidem in the United States 2003–2012
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.